Summary

MRK and MRKON both provide exposure connected to Merck & Co., Inc., but they are not the same financial instrument.

MRK is Merck's common stock listed on the New York Stock Exchange.

MRKON, also styled MRKon, is an Ondo tokenized-stock product designed to provide economic exposure linked to MRK through blockchain-based infrastructure.

The distinction affects legal ownership, shareholder rights, dividends, trading infrastructure, liquidity, custody and regulation.

The simplest framework is:

Merck = company

MRK = Merck common stock

MRKON = tokenized economic exposure linked to MRK

Readers unfamiliar with the tokenized product can begin with What Is MRKON? A Complete Guide to Merck (Ondo Tokenized Stock).

What Is MRK?

MRK is the ticker for Merck & Co., Inc. common stock.

Merck is a global pharmaceutical and Animal Health company with major businesses across oncology, cardiometabolic and respiratory medicine, vaccines, infectious disease and other therapeutic areas.

Its current financial profile is heavily influenced by KEYTRUDA.

In Q2 2026, Merck reported worldwide sales of $16.6 billion, while KEYTRUDA and KEYTRUDA QLEX together generated $8.366 billion. WINREVAIR generated another $588 million, up 75% year over year.

Investors buying MRK therefore own equity in a company whose value reflects both its existing drugs and the probability-adjusted commercial potential of its future pipeline.

What Is MRKON?

MRKON is the Ondo tokenized Merck product.

It is not issued by Merck and should not be confused with a pharmaceutical cryptocurrency.

Its purpose is to represent economic exposure linked to MRK through a tokenized financial structure.

The relationship is:

Merck pharmaceutical business

↓

MRK equity valuation

↓

MRKON tokenized exposure

MRKON vs MRK: Key Differences

1. Ownership Is the Fundamental Difference

Buying MRK through conventional securities infrastructure means purchasing an equity security issued by Merck.

MRKON is a different legal instrument.

It is designed to provide economic exposure linked to MRK, but tokenized economic exposure should not automatically be interpreted as conventional share ownership.

That affects areas such as:

• voting rights;
• custody;
• dividend handling;
• corporate actions;
• redemption.

2. Merck Issues MRK, Not MRKON

MRKON is not part of Merck's drug-development or financing strategy.

Merck does not use MRKON as:

• a utility token;
• a loyalty token;
• a healthcare blockchain asset;
• a financing token for clinical trials.

The underlying company remains a conventional publicly traded pharmaceutical company.

That means fundamental analysis should begin with drug sales, pipeline development and valuation—not tokenomics.

3. Both Ultimately Depend on KEYTRUDA

KEYTRUDA remains Merck's largest commercial franchise.

Q2 2026 KEYTRUDA and KEYTRUDA QLEX sales reached $8.366 billion, approximately half of company sales.

That concentration means MRK can be particularly sensitive to:

new KEYTRUDA indications

competition

patent developments

biosimilar timing

KEYTRUDA QLEX conversion

Because MRKON references MRK, those same fundamental factors can flow into MRKON.

4. Both Are Increasingly Exposed to WINREVAIR Growth

WINREVAIR has quickly become one of Merck's most important newer products.

Q2 2026 sales reached $588 million, up 75% year over year.

Merck is also exploring additional indications.

Its Phase 2 CADENCE trial in combined post- and precapillary pulmonary hypertension associated with heart failure with preserved ejection fraction met its primary endpoint and supported advancement toward a registrational Phase 3 program.

If WINREVAIR expands successfully, it could help diversify Merck's earnings beyond oncology.

5. Clinical Trial Risk Is Embedded in Both Instruments

Pharmaceutical stocks can reprice quickly when clinical data changes expected future revenue.

The sequence is often:

promising mechanism

↓

Phase 1/2 data

↓

Phase 3

↓

regulatory review

↓

commercial launch

Success at one stage does not guarantee success at the next.

MRK reflects those changing probabilities.

MRKON then inherits the market's interpretation through its exposure to MRK.

6. Dividends Are Handled Differently

Direct MRK ownership uses conventional stock-market dividend procedures.

Ondo describes its tokenized stocks as total-return trackers. Applicable dividends are reinvested into the underlying exposure after relevant withholding taxes rather than necessarily appearing as a traditional cash dividend to tokenholders.

This means investors should distinguish:

direct dividend receipt

from

economic dividend exposure.

7. Trading Infrastructure Is Different

MRK trades through traditional equity-market infrastructure.

MRKON trades through tokenized markets.

Eligible users can access the MRKON/USDT Spot market on MEXC.

This can make the transaction interface more familiar to crypto-native users, but it does not simplify the underlying investment.

Merck remains a complex pharmaceutical company whose valuation depends on drug economics.

8. Market Hours Can Create Temporary Pricing Differences

MRK trades according to U.S. equity-market sessions.

Tokenized markets can operate through different trading windows.

Suppose Merck releases Phase 3 data while the NYSE is closed.

MRKON market participants may begin repricing the expected impact before conventional MRK trading resumes.

Temporary differences can therefore emerge between:

the previous MRK closing price

and

the current tokenized-market price.

Sarah Chen: MRKON Adds a Wrapper, Not a New Pharmaceutical Thesis

According to MEXC senior analyst Sarah Chen, the easiest mistake is to analyze MRKON as though tokenization created a new underlying asset.

"The economic story still begins with Merck. If KEYTRUDA loses share faster than expected, a Phase 3 program fails or a new drug becomes a blockbuster, MRK is where those expectations are first reflected."

Tokenization adds a second layer.

"MRKON investors also need to understand liquidity, custody and tokenholder rights. But those questions come after the pharmaceutical analysis, not before it."

Which Is Better: MRK or MRKON?

Neither is universally better.

A user seeking conventional Merck common-stock ownership is evaluating MRK.

A user seeking tokenized economic exposure linked to Merck is evaluating MRKON.

The useful question is therefore:

Which financial structure gives me the type of exposure and rights I actually want?

FAQ

Is MRKON the same as MRK?

No. MRK is Merck common stock. MRKON is an Ondo tokenized product linked economically to MRK.

Does Merck issue MRKON?

No.

Does MRKON give direct Merck shareholder rights?

It should not be treated as legally identical to conventional MRK ownership.

Does KEYTRUDA affect MRKON?

Indirectly, yes. KEYTRUDA is Merck's largest product franchise, so changes in its commercial outlook can materially affect MRK valuation.

Does MRKON include dividend exposure?

Ondo describes its tokenized stocks as total-return trackers incorporating reinvested dividends after applicable withholding taxes.

Conclusion

MRK and MRKON represent the same underlying pharmaceutical story through different structures.

MRK is Merck equity.

MRKON is tokenized economic exposure linked to that equity.

For both, the important drivers remain:

KEYTRUDA

WINREVAIR

the pipeline

clinical data

regulatory approvals

patent protection

MRK valuation

Tokenization changes access and market structure. It does not change Merck's pharmaceutical fundamentals.